research
The Tumor's Acidity Rewired Drug Resistance
An ERK–p300–PARP1 pathway helped ovarian-cancer models evade PARP inhibitors and offered a route to resensitization.
Summary
An ERK–p300–PARP1 pathway helped ovarian-cancer models evade PARP inhibitors and offered a route to resensitization.
MD Anderson researchers found that acidic conditions activated ERK, p300 and PARP1 signaling that reduced PARP trapping and made ovarian-cancer cells less sensitive to PARP inhibitors. Blocking p300 restored drug sensitivity across preclinical models, including resistant ones; the result supports future combination studies but does not yet establish patient benefit.
Why it matters
An ERK–p300–PARP1 pathway helped ovarian-cancer models evade PARP inhibitors and offered a route to resensitization.
Limits and context
- Blocking p300 restored drug sensitivity across preclinical models, including resistant ones; the result supports future combination studies but does not yet establish patient benefit.
Key claims
An ERK–p300–PARP1 pathway helped ovarian-cancer models evade PARP inhibitors and offered a route to resensitization.
Qualification: Blocking p300 restored drug sensitivity across preclinical models, including resistant ones; the result supports future combination studies but does not yet establish patient benefit.
Evidence: source-2026-07-30-011
Sources
- MD Anderson via Newswise: Acidic tumor pathway drives PARP-inhibitor resistanceMD Anderson · secondary reporting
Corrections
No corrections have been recorded for this story.